HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial - Summary - MDSpire

HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial

  • By

  • Lixin Guo

  • Zilin Sun

  • Lihui Zhang

  • Guijun Qin

  • Yulan Li

  • Xiaopan Chen

  • Na Xu

  • Xiuhai Su

  • Li Mao

  • Jiao Sun

  • Zhifeng Cheng

  • Xiaoguang Shi

  • Fang Wang

  • Qi Wang

  • Ruirong Pan

  • Shan Ding

  • Zi Ye

  • Yimei Xu

  • Pan Liu

  • June 3, 2026

  • 0 min

Share

Objective:

To evaluate the efficacy and safety of once-daily oral HRS-7535 as add-on therapy to metformin in adults with type 2 diabetes inadequately controlled by metformin.

Key Findings:
  • HRS-7535 showed a reduction in HbA1c levels compared to placebo, as reported in the study.
  • The safety profile was consistent with other GLP-1 RAs, with no unexpected adverse events reported.
  • Participants receiving HRS-7535 showed improvements in fasting plasma glucose and body weight, as indicated by the study.
Interpretation:

Limitations:
  • The study was limited to a specific population in China, which may affect generalizability.
  • Short duration of the trial may not capture long-term efficacy and safety.
Conclusion:

Original Source(s)

Related Content